Hansa Biopharma announced that it has attained reimbursement in the Czech Republic for its first-in-class treatment, Idefirix«, for the desensitization treatment of highly sensitized adult patients prior to kidney transplant from a deceased donor. Between January and October 2022, a total of 386 kidney transplants from deceased donors were performed in the Czech Republic, while approximately 400 patients remained on the kidney transplant waiting list. Highly sensitized patients have antibodies with a broad reactivity against a wide pool of potential donors, so finding a matched organ for these patients is particularly challenging.

As a result, highly sensitized patients end up spending a longer than average time on transplant waiting lists with an increased risk of dying while waiting for a compatible donor. The decision to implement Idefirix« marks an important milestone for highly sensitized patients in the Czech Republic as they may now be desensitized using Idefirix« to enable kidney transplantation.